Pyrrolidone carboxamides
    1.
    发明授权
    Pyrrolidone carboxamides 失效
    吡咯烷酮甲酰胺

    公开(公告)号:US07067549B2

    公开(公告)日:2006-06-27

    申请号:US10500604

    申请日:2002-12-27

    IPC分类号: A61K31/403 C07D209/82

    摘要: Pyrrolidone carboxamides of formula (I) where R2=a group of formula (a) or (b), R5=phenyl, heteroalkyl, aryloxy, alkoxy, alkanoyl or —NR6R7 and R1, X, R3, R4, R6 and R7 have the meanings given in the description and the claims, pharmaceutically applicable acid addition salts with basic compounds of formula (I), pharmaceutically applicable salts of acid compounds of formula (I) with bases, pharmaceutically applicable esters of hydroxy- or carboxy-group containing compounds of formula (I) and hydrates and solvates thereof, inhibit the interaction of neuropeptide Y (NPY) with one of the neuropeptide receptor subtypes (NPY-Y5) and are particularly suitable for the prevention and treatment of arthritis, diabetes and especially eating disorders and obesity. The above can be produced by known methods and converted into a galenic dosage form.

    摘要翻译: 式(I)的吡咯烷酮甲酰胺其中R 2 =式(a)或(b)的基团,R 5 =苯基,杂烷基,芳氧基,烷氧基,烷酰基或 R 6,R 7,R 12,R 11,R 4,R 4, >,R 6和R 7具有在说明书和权利要求书中给出的含义,药学上适用的与式(I)的碱式化合物的酸加成盐,药学上适用的盐 具有碱的式(I)酸化合物,含有羟基或羧基的式(I)化合物的药学上适用的酯及其水合物和溶剂合物抑制神经肽Y(NPY)与神经肽受体亚型之一的相互作用 NPY-Y5),特别适用于预防和治疗关节炎,糖尿病,特别是进食障碍和肥胖症。 上述可以通过已知方法制备并转化成盖仑剂型。